Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes
- 15 April 2009
- journal article
- Published by Elsevier BV in Experimental Cell Research
- Vol. 315 (7), 1302-1312
- https://doi.org/10.1016/j.yexcr.2009.02.001
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytesJournal of Molecular and Cellular Cardiology, 2006
- A threshold of GATA4 and GATA6 expression is required for cardiovascular developmentProceedings of the National Academy of Sciences of the United States of America, 2006
- Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte ViabilityCirculation Research, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid MalignanciesClinical Cancer Research, 2005
- Dilated cardiomyopathy in Erb-b4-deficient ventricular muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in MyocytesOnline Journal of Public Health Informatics, 2005
- Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathyJournal of the American College of Cardiology, 2004
- Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heartDevelopment, 2003
- Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2Circulation, 2002